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INTRODUCTION 
Tissue Factor biology 
Tissue Factor (TF), or Thromboplastin or CD142, is the main activator of 
coagulation cascade. It is a 47 kDa transmembrane glycoprotein consisting of 263 
amino acid organized into a 219 amino acid extracellular domain, a 
transmembrane region of 23 amino acid and a short 21 amino acid intracellular 
tail1 (Fig. 1).  
 
Figure 1. Tissue factor structure. The 47-kDa membrane bound single polypeptide chain 
consists of extracellular, transmembrane and cytoplasmic domains. There are two 
intrachain disulfide bridges, shown in blue, in the extracellular region where it also 
contains factor VII/factor VIIa binding domain. There are three serine residues, shown in 
red, in the cytoplasmic domain for undergoing phosphorylation. 
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The extracellular domain contains a catalytic site responsible for the binding with 
factor VII/VIIa binding domains; the intracellular region could undergo serine 
phosphorylations, which could modify its function2-3; for example, the cytoplasmic 
region negatively regulates TF expression, which is mediated by suppressed 
Erk1/2 phosphorylation. 
The extracellular domain of TF is structurally homologous to interferon receptors 
and the X-ray crystallography confirmed the typical cytokine receptor fold 
consisting of two tightly aligned fibronectin type III modules (TF1 and TF2); 
moreover the extracellular domain contains  chains with antiparallel folding and 
similar to the constant domain of immunoglobulins, and presents two disulfide 
bonds. In human tissue factor extracellular domain there are three N-linked 
glycosylation sites and the factor VII binding site is bordered by two of these. In 
full-length TF the last six residues (214-219) are responsible for the connection 
between the extracellular region and the transmembrane domain, and this region 
is called "stalk region". The flexibility of the “stalk region” allows the extracellular 
domain to adopt various orientations with respect to the plasma membrane4,5. The 
transmembrane domain and cytoplasmic are connected by a group of four basic 
amino acids which represents a typical pattern of transmembrane proteins. The 
cytoplasmic domain presents a acylated cysteine to a palmitate or to a stearate, 
whose physiological significance is however still unknown, and two serine 
residues, which represent two putative phosphorylation sites6. 
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Tissue Factor-initiated Extrinsic Pathway of Coagulation Cascade 
Factor VII structure 
The coagulation factor VII (FVII) is a soluble serine plasma protease synthesized 
by the liver and presents in the bloodstream in the form of activated FVII (1%) or 
in the form of the zymogen (99%), lacking of catalytic activity. The FVII consists of 
five domains: the first is an amino-terminal domain that contains gamma-carboxy-
glutamic acid (Gla) residues, also called Gla domain which binds Ca++ ions and 
contains hydrophobic residues that confer the ability of FVII to reversibly bind 
anionic phospholipids of the cell membrane. Near the Gla domain there is the 
aromatic stack (also called the helical or hydrophobic stack) that some 
investigators consider to be part of the Gla domain, and close to this domain there 
are two epidermal growth factor-like domains and the protease domain7,8. 
TF initiates the extrinsic blood coagulation, which proceeds as Ca++-dependent 
extracellular signaling to sequentially activate zymogens FVII, factor X (FX), and 
prothrombin (FII) for the generation of coagulant mediators: FVIIa, FXa and 
thrombin (FIIa), respectively. As a result, thrombin cleaves off fibrinogen into 
fibrin monomers that cross-link to produce insoluble blood clots (fig. 2). The 
complex TF-FVII can be activated by circulating factor VIIa complex or by the TF-
VIIa, using a self-triggering mechanism, or through a positive feedback activation 
by other proteases (Xa, IXa, thrombin). The combination of the two factors 
promotes the alignment of the active site of VIIa with the cleavage site of the 
substrate bound to the membrane4. The physiological substrates of this complex 
are factor IX and factor X, which bind reversibly to anionic phospholipids of the 
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membrane9. Factor X can be activated by TF-VIIa complex or by the complex IXa-
VIIIa-phospholipid-Ca++. The factor IXa is assembled on membrane phospholipids 
and in the presence of its cofactor, factor VIIIa, catalyzes the activation of factor Xa, 
that induces platelet activation and the formation of a fibrin clot10. The anionic 
membrane phospholipids, such as phosphatidylserine, play an important role in 
the beginning of the TF-dependent coagulation, promoting both TF-factor VIIa 
complex activity and the binding of factors IX and X. 
 
Figure 2. TF-depending pathway of coagulation cascade. 
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Catalytic regulation of TF-factor VIIa complex 
The only physiological inhibitor of the TF-FVIIa complex is the tissue factor 
pathway inhibitor (TFPI). The TFPI is a serine protease consisting of a carboxyl-
terminal basic domain, followed by three protease domains repeated in tandem, 
denominated Kunitz domains (KI-II-III), and an amino terminal acid region. The 
TFPI is mainly synthesized by the vascular endothelium but a small percentage is 
found platelets or circulating in plasma, free and/or associated with lipoproteins. 
The mechanism of inhibition of the extrinsic pathway of coagulation by TFPI 
occurs in two steps (Fig. 3): 
1) TFPI binds to factor X through the KII domain and inhibits its activity. Also the 
carboxy-terminal end is required for the rapid and efficient inhibition of FXa; 
2) TFPI-Xa complex binds to TF-FVIIa complex and neutralizes its catalytic activity: 
in the presence of Ca++ a quaternary complex TFPI-FXa-FVIIa-TF is formed11. 
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Figure 3. Regulation of TF-factor VIIa complex and mechanism of action of TFPI. The TFPI 
is a protease inhibitor with three domains inhibitors repeated in tandem (I, II, III) located 
mainly on the endothelial surface or free in plasma binding to lipoprotein. Mechanism of 
action: as first the free TFPI (a) binds and inhibits factor Xa (b), subsequently TFPI-factor 
Xa complex neutralizes the TF-factor VIIa complex forming a quaternary complex (c). 
 
 
Tissue Factor: not only thrombosis and haemostasis. 
Although the main physiological function of TF is the regulation of the processes of 
hemostasis and thrombosis, emerging evidences showed a broad spectrum of 
biological function of tissue factor. TF overexpression or hypercoagulability often 
observed in many pathological conditions expand its role in cardiovascular 
complications, diabetes, angiogenesis, tumor metastasis, wound repairs, 
embryonic development, cell adhesion/migration and in autoimmune disorders.  
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Cardiovascular complications are closely associated with either inflammation or 
thrombosis and TF plays a major role in their pathogenesis. It has been 
demonstrated that TF is expressed in lipid-rich human atherosclerotic plaques and 
it is an important determinant of the thrombogenicity of human atherosclerotic 
lesions12. Moreover TF hypercoagulability leads to cardiovascular complications 
and vascular disease such as arterial hypertension13, hypertrophy14 and acute 
coronary syndrome15,16.  
In conditions of hyperglycemia, such as in Type I and Type II diabetes, the 
excessive plasma glucose conjugates with plasma proteins, such as hemoglobin, 
determined the advanced glycation endproducts (AGEs) formation; the increased 
circulating AGEs lead to an increased expression of tissue factor making diabetes a 
hypercoagulable and thrombotic condition17. TF can also assume a pathogenic role 
in diabetic progression in a close relation with the inflammatory process: TF could 
be responsible for insulin resistance18,19. Many studies suggested that TF is not 
only essential for haemostasis, but also participates in crucial steps of blood vessel 
formation and remodeling20,21. The most interesting findings in this regard are the 
results of the TF gene disruption in mice, which produced an early lethality of 
more than 90% of TF knock out embryos in utero between E8.5 and E10.521. TF 
has also an important role in angiogenesis and tumor metastasis22. In the adult 
animal tumor growth and especially the tendency to metastasis are influenced by 
the presence of TF, which plays a critical role in the processes of 
vascularization/angiogenesis. Increased expression of TF contributes to regulating 
the angiogenic properties of tumor cells, altering the production of regulatory 
molecules of endothelial growth, such as vascular endothelial growth factor. The 
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expression of TF also influences cell adhesion and motility. Its role in cell migration 
and adhesion explains the passage of tumor cells through the endothelial barrier. 
Many studies demonstrated the importance of TF in adherence and subsequent 
transmigration of mononuclear phagocytes through the endothelium23.  
A better understanding of the structure of TF, which shows homology with the 
superfamily of cytokine receptors, led to study the intracellular mechanisms 
triggered upon binding with FVII, while, on the extracellular surface, a series of 
reactions initiates the extrinsic pathway of coagulation. The initial stages of signal 
transduction due to the formation of the complex TF-FVIIa are still little known. 
However, some studies in cell lines have shown that, unlike cytokine receptors, the 
cytoplasmic domain of TF is not always directly involved24. The most accepted 
hypothesis is that TF does not behave like a receptor, as it causes a conformational 
change of FVIIa, such as to activate a membrane protein, probably identified in the 
receptor protease activated receptor-2 (PAR-2)25. PAR-2 is a G protein-coupled 
receptor, and its activation determines the phosphorylation of kinases, which gives 
rise to subsequent phosphorylation cascades that lead to an amplification of the 
signal and activation of specific metabolic pathways (fig. 4). The TF-FVIIa complex 
formation can also induce the mobilization of intracellular Ca++ after the activation 
of G protein/phospholipase C, the activation of small G proteins (such as Rac and 
Cdc42 ), the phosphorylation of tyrosine kinases of the Src family that in turn 
activate phosphatidylinositol 3-kinase (PI3K)26. The PI3K phosphorylates protein 
kinase B, also known as Akt, responsible for the cytoskeleton reorganization and 
the cell migration, and triggers by Rac and Cdc42 the phosphorylation of mitogen 
activated protein kinase (MAP kinase) that, once translocated into the nucleus, 
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promotes the expression of the so-called "immediate-early genes," that are genes 
whose expression occurs in the absence of a previous protein synthesis. These 
genes, activated by TF, encode for transcription factors, growth factors, receptors, 
regulators of the cellular organization and motility and for some cytokines, thus 
suggesting the presence of a positive feedback in increasing the expression of TF27. 
 
 
Figure 4. Schematic view of intracellular signal pathways activated by TF-FVIIa complex. 
The signal is transferred over the membrane by a protease-activated receptor (PAR2) that 
activates a trimeric G-protein and phospholipase C (PI-PLC) and, as a consequence of this, 
a rise in intracellular calcium concentration is observed. The mitogen activated protein 
kinases (MAPK) extracellular signal-regulated kinase 1/2 (Erk), c-jun N-terminal kinase 
(JNK), and p38MAPK are activated and the transcription of immediate early genes is 
increased. Members of the Src tyrosine kinase family are phosphorylated, resulting in cell 
migration and cytoskeletal reorganization.  
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However, some studies showed the evidence that the pro-metastatic role of TF is 
due even to the cytoplasmic domain because of the phosphorylation of at least two 
serine residues present within the C-terminal TF domain. The intracellular domain 
of TF can interact directly with the cytoskeletal components through a protein, 
filamin-1 (also known as actin-binding protein 280, ABP-280), forming a protein 
complex involved in the remodeling of the actin filaments, responsible for the 
morphology and cell motility28. The complexity of the different mechanisms by 
which the TF-FVIIa complex influence the morphology and cell motility and 
induces the expression of immediate early genes, indicates an activated status of 
the cell, induced by TF and relevant for the uncontrolled growth and/or the 
metastasis of cancer cells, that often express TF on their surface. 
 
 
Vessel wall-derived Tissue Factor 
In 1987 TF cDNA was cloned by four independent groups from adipose29, 
fibroblast1 and placental30-31 cDNA libraries. However, there was no information 
concerning the cellular distribution of TF-producing cells within the tissue from 
which it has been isolated. It has been postulated that TF is not present in the 
vessel wall cells that come in contact with blood but must be associated with the 
vasculature where it could act quickly in response to vascular damage. Since the TF 
cDNA cloning a series of studies was conducted in order to evaluate TF expression 
and localization under physiological and pathological conditions. In 1989 Wilcox 
and colleagues reported the localization in the normal human vessel wall and in 
the atherosclerotic plaque of both TF messenger RNA (mRNA), by in situ 
Introduction 
 
 12 
hybridization, and protein, using specific antibody in immunohistochemistry32. In 
1996 Thiruvikraman et al., using digoxigenin-labeled factors VIIa and X, showed 
the evidence that the lipid rich core of atherosclerotic plaques contains high levels 
of extracellular TF able to bind its physiological ligand. The authors concluded that 
this location may be responsible for the rapid initiation of thrombosis after the 
lipid rich atherosclerotic plaques rupture and the core contents are exposed to 
flowing blood33. In the same year the same research group further confirmed the 
direct contribution of TF to the procoagulant activity of human coronary atheroma 
showing that it was significantly reduced if the samples were pretreated with a 
blocking anti-TF antibody34. In 1997 it was demonstrated that the amount of TF 
present in an atherosclerotic plaque is directly correlated to the plaque 
thrombogenicity35. At the beginning of 2000 Jander et al. supported this concept 
showing that human carotid plaques with an high content of TF are most 
frequently found in symptomatic patients (fig. 5)36. 
 
Figure 5. TF expression in human carotid endoarterectomy specimens detected by 
immunohistochemistry using a monoclonal mouse antibody. TF content in the plaque from 
symptomatic patient (A) is higher than that present in the plaque isolated from 
asymptomatic patients (B). Scale bar 1mm.  
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In pathological condition, such as in atherosclerosis, the cells of the vessel wall, 
endothelial cells and smooth muscle cells, and other cells, such as monocytes, can 
be induced to expressed TF. Indeed, in an atherosclerotic vessel TF is expressed by 
perturbed endothelial cells32, by infiltrated monocytes-macrophages15-16 and by 
smooth muscle cells32,33, besides by the fibroblasts of the tunica adventitia which 
constitutively express the protein. The TF produced by these cells is the so-called 
vessel wall-derived TF37. 
In an atherosclerotic setting polymorphisms in the TF gene promoter should also 
be considered as factor that can induced TF expression. Four polymorphisms have 
been described in TF promoter: three single nucleotide polymorphisms, the -603 
A7G, the -1322 C/T and the -1812 C/T, and one deletion/insertion -1208 I/D. 
These polymorphisms give rise to two haplotypes with almost equal frequency: the 
603A and the 603G haplotype38. Polymorphisms in TF gene promoter can 
modulated TF expression and thereby its involvement in atherosclerosis and 
individual predisposition to atherosclerotic disease38,39. 
Based on these data, at the end of the last century, the scientific community was 
quite convinced that the vessel wall-derived TF plays a key role in the 
thrombogenicity of the atherosclerotic plaque and in the inhibition of TF pathway 
could open new therapeutic strategy in the prevention of acute coronary 
thrombosis after plaque disruption40,41. 
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Platelet-associated Tissue Factor 
For long time it was believed that the contribution of platelets in atherothrombotic 
disease was confined only to the formation of thrombus. In recent years, thanks to 
technological advances and new methodologies available, such as transcriptomic 
and proteomic, we have completely changed our knowledge of the platelet 
functions and activities, not only in the intravascular compartment but also in the 
extravascular milieu42. Platelets have been considered biological simple cells but 
recent findings indicate that platelets perform novel and complex biological 
functions. Platelets have been considered not able to express new genes because 
they don’t have a nucleus; in 2003 Gnatenko and colleagues described for the first 
time platelet transcriptome43. Today we know that platelets have an average of 
three to seven thousand messenger RNA involved in different cellular activities 
(metabolisms, cell signaling) and used by platelets to do de novo protein synthesis. 
This transcriptome derived from megakaryocytes through a very well controlled 
mechanisms: in 2011 Cecchetti et al. provide the evidence that not all messenger 
RNA are transferred from megakaryocytes to platelets, but it depending on 
physiological or pathological conditions44. We was used to think that platelets are 
short-acting cells when organized into a clot, but today we know that platelets are 
long-lived and can mediate cell-cell interactions for many hours after initial 
activation.  
Taking advantage of these new findings in the platelet biology, the contribution of 
these cells has been deeply revisited. Platelets are no more considered key player 
only in thrombus formation occurring upon plaque rupture, but they play an 
important role in the inflammatory process, playing a key role in atherothrombotic 
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disease in the early stages of the plaque development by releasing numerous 
cytokine (IL- 1β, CD40L, β-thromboglobulin, etc.), chemokines (RANTES, PF4, 
ENAP-78, etc.), growth factors (PDGF, TGF, EGF, bFGF, etc.) and adhesion proteins 
(fibrinogen, fibronectin, von Willebrand factor, etc.)42,45. 
Concomitant with this new vision of the role of platelets in atherothrombosis, at 
the beginning of 2000, Rauch et al. proposed that thrombosis occurring upon 
plaque rupture does not necessarily require the exposure of vessel wall-TF46. 
Platelets can be a source of active TF, the so called “blood-borne” TF or 
“circulating” TF, which can sustain the activation of the blood coagulation on the 
edge of a growing thrombus. The author’s theory was based on the observation 
that TF antigen is circulating in the blood and its levels increased in different 
pathological conditions47,48; moreover circulating TF is associated with increased 
blood thrombogenicity49 and procoagulant microparticles (MPs) was found in 
human blood under normal and pathological conditions50,51.  
In the 2000, Rauch and Nemerson published the finding that TF-positive 
microparticles released by activated monocytes and granulocytes were up taken 
by activated platelets through a CD15-P-selectin transfer mechanism. The authors 
suggest that platelet-associated TF, resulting from TF-positive MPs transfer, is an 
alternative source of procoagulant activity necessary for the thrombus to growth46.  
In 2003 Camera et al52 and Müller et al53 showed the evidence that human platelets 
from healthy donors express TF antigen, using different approaches (western 
blotting, confocal and immune electron microscopy). Moreover, Camera and 
colleagues reported, by using flow cytometry, that platelet activation resulted in 
the expression of TF besides P-selectin and all other markers of platelet activation, 
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on the cell surface (fig. 6). The presence of TF protein and its functional activity 
was further confirmed showing the binding of this protein to its physiologic ligand 
FVIIa, and the capacity to generate FXa52.  
 
Figure 6. TF and P-selectin localization in activated platelets. ADP-stimulated platelets 
were stained with monoclonal mouse antibody against TF and P-selectin (green). The red 
staining represents the platelet population marker GpIIb (CD41). Immunolocalization was 
assessed by confocal microscopy. Scale bar, 5µm.  
 
 
As mentioned above, the first evidence of platelet transcriptome was published in 
200343. In the same year, TF mRNA was found in appropriate sample resting 
human platelets devoided of leukocytes contamination, suggesting that platelets 
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could de novo protein synthesis52. Three years later, two independent groups 
provided the evidence that platelet activation results in the translation of TF 
mRNA, increasing the membrane-bound TF protein54,55.  
At present, published data suggest that three are the possible mechanisms 
responsible for the presence of TF in human platelets: 1) the transfer from TF-
positive MPs released by activated endothelial cells or leukocytes, as proposed by 
Rauch and Nemerson46; 2) the storage of TF protein within the α-granules35,36 and 
finally 3) the de novo protein synthesis from specific TF mRNA (fig. 7). All these 
pathways are not mutually exclusive, and one mechanism may dominate over the 
others depending on the pathophysiologic conditions. 
 
Figure 7. Schematic view of the three possible mechanisms responsible for the presence of 
TF in human platelets. 
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In the last 25 years, research in the field of atherosclerosis has clearly established 
the role of TF as the principal trigger for arterial thrombosis. Recent data support 
the concept that the thrombus propagation takes also advantage of the blood-born 
TF, which consists of microparticles- as well as platelet-associated TF. Moreover, in 
the last years data showing increased levels of platelet-associated TF in 
pathological conditions such as essential thrombocytopenia56, cancer57 and 
diabetes58 have been accumulated. 
Despite all these evidence it is worth of mentioning that the issue of platelet-
associated TF is still a matter of intense debate among the scientific community. 
Many investigators do not detect TF activity in platelets and they argue that the 
only circulating cells capable of synthesizing TF are monocytes that may be the 
only source of TF-induce thrombosis when the endothelium is intact59-61. These 
investigators claim that the discrepancies of the published data depend on 
differences in methods, reagents and experimental conditions. The data of those 
able to found tissue factor in platelets, show that the expression of platelet-
associated TF is the result of a dynamic process; thus its detection can 
considerably differ if observed at different times after in vitro cells stimulation. 
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Platelets biology  
Platelets, or thrombocytes, are anucleated discoid cell fragments without nucleus 
and with size of 1-4 µm in diameter and 1 µm thick. Platelets are formed and 
released into the bloodstream by precursor cells called megakaryocytes. 
Megakaryocytes are rare myeloid cells that reside within the bone marrow and 
represents less than 0.1% of the myeloid cells62; they are also found in the lung and 
in the bloodstream. Megakaryocytes tailor their cytoplasm and membrane systems 
for platelet biogenesis. Before a megakaryocyte has the capacity to release 
platelets, it enlarges considerably to an approximate diameter of 100 μm and fills 
with high concentrations of ribosomes that facilitate the production of platelet-
specific proteins63. Cellular enlargement is mediated by repeated cycles of 
endomitosis, a process that amplifies the DNA by as much as 64-fold64. The platelet 
release by megakaryocytes involves the development of cytoplasmic ramifications, 
the so called “pro-platelets” of 100-500 µm of length. This process generally starts 
from a single site on megakaryocyte with the emission of pseudopodal extensions 
that in a period of 4-10 hours stretch in pro-platelets. In the final portion of the 
pro-platelet, the bundles of microtubules form loops that come out and fall in pro-
platelet causing the formation of bulbous tips of 3-5μm in diameter (fig 8)65. 
Introduction 
 
 20 
 
Figure 8. Schematic overview of platelets release by megakaryocytes. (B) Megakaryocytes 
maturation is characterized by repeated cycles of endomitosis and by a significant 
maturation of the cytoplasm with the formation of internal membranes, granules and 
organelles while the microtubules extend (C). Shortly before the formation of pro-
platelets, microtubules are consolidated into a mass beneath the plasma membrane and 
blend in linear beams thicker branches that fill pro-platelets determining the elongation 
(D). In the terminal portion of the pro-platelets, the bundles of microtubules form loops 
that come out and fall in pro-platelets causing the formation of bulbous tips. (E) The entire 
cytoplasm of megakaryocytes is converted into pro-platelets that are released from the 
cell. The individual platelets are then released from the ends of pro-platelet. 
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Platelets are released by megakaryocytes, circulate in the vessels without adhering 
to the vascular wall. Although the prevention of bleeding is their physiological role, 
platelets have other important functions, for example in inflammatory processes, 
being a rich source of chemokines, cytokines and growth factors that are stored 
into the granules66. Platelets in the peripheral blood are approximately 250,000/l 
and a decrease in their values below 100,000/l takes the name of 
thrombocytopenia. Their average lifespan is about 8-10 days, after which time they 
reach senescence and they are removed from the bloodstream by the spleen and 
liver, and this mechanism also works in the case of morphological or functional 
abnormalities of platelets. 
Structurally, platelets consist of: 
- A plasma membrane rich in phospholipids including phosphatidylserine and 
phosphatidylinositol, negatively charged and abundant in the cytoplasmic side of 
the membrane where they act as a substrate for the phospholipase. The glycocalyx 
is rich in glycoproteins, some of which perform receptor functions in response to 
stimuli and agonists, giving to the platelets the ability to convey information and to 
give rise to a cellular response67. 
- Internal membranes formed by the open canalicular system and by the tubular 
dense on which are anchoring the enzymes involved in the synthesis of 
prostanoids. 
- A cytoskeleton composed of microtubules and microfilaments, which are 
important in the process of platelet activation and secretion. 
- Mitochondria, lysosomes and peroxisomes. 
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- Secretory granules. Platelets contain three types of granules: lysosomes, dense 
granules (also called delta granules) and α-granules. The content of the dense and 
alpha granules is secreted, during the platelet response, directly in the 
microenvironment seat of platelet aggregation. Among the molecules contained in 
the granules there are ADP, Ca++, serotonin, content in the delta granules, 
fibrinogen, thrombospondin, PF- 4 and PAI-1, content in α-granules. 
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AIMS OF THE STUDY 
Tissue factor is the main activator of the coagulation cascade. It is a 
transmembrane glycoprotein with an extensive extracellular region responsible 
for the binding with FVII. The formation of TF-FVIIa complex results in the 
activation of factors X and FIX, which are responsible for the formation of fibrin 
from fibrinogen4. Unlike all the other coagulation factors that are synthesized by 
the liver and are released into the circulation, tissue factor is not synthesized by 
liver and it’s not present in the bloodstream. TF is normally absent from vascular 
cells that come in contact with blood and it is typically expressed only by 
fibroblasts of the tunica adventitia6. However in pathological conditions the cells of 
the vessel wall, endothelial cells and smooth muscle cells, and other cells, such as 
monocytes, can be induced to express TF. Indeed in atherosclerotic vessel TF has 
been detected in endothelial cells, smooth muscle cells and monocytes68. At the 
beginning of 2000 Nemerson et al. showed the evidence that, among the circulating 
cells, also platelets can be a source of TF, and so they are not only involved in 
hemostasis but they are also cells able to trigger themselves the coagulation 
cascade50. Published data suggest that three are the mechanisms responsible for 
the presence of tissue factor in platelets: 1) the first and the most shared among 
the scientific community is the transfer from TF positive microparticles released 
by activated endothelial cells or leukocytes. 2) TF may also be present as a protein 
stored in the alpha-granules of platelets and can be exposed on the plasma 
membrane upon activation. 3) platelets may contain the messenger RNA coding for 
the TF that can be used to do de novo protein synthesis. Today we know that 
platelet have a trascriptome derived from megakaryocytes through a very well 
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controlled process. In 2003 our group showed the evidence that megakaryocytes 
derived from CD34 positive cells and human platelets have TF mRNA but the 
evidence that the TF mRNA and protein present in platelets are the result of a 
direct megakaryocyte transfer mechanism is still lacking.  
Moreover, different groups have then characterized TF in platelet by using 
different methodologies (confocal and electron microscopy, ELISA, Western 
blotting, flow cytometry, functional activity assays)52-55,70-72. Despite this in-depth 
characterization, the platelet-TF is matter of controversy by some authors that, 
failing to identify TF in platelets, argue that the published data are artifacts, thus 
generating an ongoing debate73,74. 
In addition, it has to be considered that the study of human megakaryocytes and 
platelets is fundamentally hampered by the difficulty of finding megakaryocytes: 
indeed, these cells represent only the 0.01-0.1% of bone marrow cells and their 
location is clearly not easily accessible.  
Furthermore, it is far easier to work with human platelets being certain to work 
with a population free of leucocyte contamination. 
Based on this background the aims of this work were: 
 To develop an experimental in vitro system of platelet production from 
cultured human megakaryocytes (Meg-01 cells) in order to study platelet 
protein expression in the absence of any cross-talk with other cellular and 
subcellular (microparticles) entities; 
 To assess the expression of TF mRNA and protein in human Meg-
megakaryoblasts, Meg-megakaryocytes and Meg-platelets; 
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 To assess the functional activity (i.e. capability to trigger thrombin 
generation) of TF expressed by human Meg-megakaryoblasts, Meg-
megakaryocytes and Meg-platelets; 
 To verify the capability of human Meg-megakaryocytes to transfer TF 
mRNA to nascent platelets;  
 To confirm data obtained with Meg-01 by using human CD34+-derived 
megakaryocytes; 
 To dissect the contribution of platelet-TF to the global platelet haemostatic 
capacity by down regulation of TF expression in Meg-megakaryoblasts by 
stable silencing through a lentiviral shRNA approach. 
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METHODS 
Antibodies and reagents 
Mouse anti human CD41-PerCP-Cy5.5, CD107 PECy7, Tissue Factor (CD142)-PE, 7-
Aminoactinomycin D (7-AAD), Violet proliferation dye 450 (VPD), Annexin V-APC, 
BD Trucount tubes, BD Cytometer Setup and Tracking Beads and BD Comp Beads 
were purchased from BD Biosciences (San Jose, CA, USA). Mouse anti human CD61-
PE was from Beckman Coulter (Brea, CA, USA); mouse anti human TF 4507JC FITC, 
mouse anti human TF 4509, goat anti human TF 4501 and Actichrome TF were 
from American Diagnostica Inc. (Stamford, CT, USA). Fab9012.2 anti GpVI and 
R27E4 anti α2β1 were kindly provided by Prof. De Marco (Department of 
Laboratory Diagnostics and Cellular Therapy, IRCCS, C.R.O., Aviano, Pordenone, 
Italy). Lactadherin (Recombinant Mouse MFG-E8) was from R&D System 
(Minneapolis, MN, USA). TF 4509, GpVI, α2β1 and Lactadherin were labeled with 
Alexa Fluor 488 or Alexa Fluor 633 labeling kit (Molecular Probes, Eugene, OR, 
USA) according to manufacturer instructions. All the antibodies have been titrated 
in both Meg-platelets and Meg-01 samples. Calibrated beads (1 and 4 µm) were 
from Molecular Probes. All the chemicals were from Sigma-Aldrich (St. Louis, MO, 
USA). Immunomagnetic beads were from Milteny-Biotec (Bergisch Gladbach, 
Germany); Stem Spam medium was from Stem Cell Technologies (Vancouver, 
Canada). The human megakaryoblastic cell line, Meg-01, was obtained from the 
American Type Culture Collection (Manassas, VA, USA). RPMI 1640 medium, L-
glutamine and Penicillin-Streptomycin were from GIBCO (Life Technologies, 
Carlsbad, CA, USA). Fetal bovine serum (FBS) was from EuroClone (Pero, MI, Italy); 
valproic acid (VPA), fibrinogen, TRAP-6 and propidium iodide (PI) were from 
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Sigma-Aldrich; RNaseA was from Roche Applied Science (Penzberg, Upper Bavaria, 
Germany); thrombopoietin (TPO), interleukin-6 (IL-6) and interleukin-11 (IL-11) 
were from PeproTech (EC Ltd, London, UK). Human serum albumin (HSA) was 
from CSL Behring (King of Prussia, PA, USA). Zymutest total TF kit was from 
HYPHEN BioMed (Neuville-Sur-Oise, FRANCE); Bradford protein assay and iQ™ 
SYBR® Green supermix were from Bio-Rad Laboratories (Munich, Germany); 
miRNeasy Mini kit for RNA extraction was from Qiagen (Venlo, The Netherlands). 
All the reagents for RealTime PCR experiments were from Life Technologies 
(Carlsbad, California, USA); all the reagents for thrombin generation assays were 
from STAGO (Asnières sur Seine, France). Collagen was from Mascia Brunelli 
(Milan, Italy); GIPZ lentiviral shRNA particles were from DASIT Sciences 
(Cornaredo, MI, Italy). 
 
Cell culture 
The Meg-01 cells were cultured in RPMI 1640 with 10% FBS, 2 mM L-glutamine, 
100 U/ml penicillin, 100 µg/ml streptomycin, at 37°C in a 5% CO2 humidified 
atmosphere. For megakaryocyte differentiation, Meg-01 cells were seeded in 10 
cm petri dishes, 400,000 cells/ml in 15ml medium, and cultured for 8 days in the 
presence of 2mM VPA.  
Human cord blood was collected on informed consent of the parents, with 
approval from the ethical committee of the Istituto di Ricovero e Cura a Carattere 
Scientifico Policlinico San Matteo Foundation in accordance with the principles of 
the Declaration of Helsinki. Human umbilical cord blood CD34+ cells were 
separated and cultured as previously described76. Briefly, CD34+ cells were 
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separated by immunomagnetic bead technique according to the manufacturer's 
instruction (purity >90%) and cultured for 12 days in Stem Span medium 
supplemented with 10 ng/mL TPO, IL-6, and IL-11, in the presence of 1% 
penicillin–streptomycin at 37°C in a 5% CO2 humidified atmosphere. The medium 
was changed at day 3, 7, and 10 of culture.  
 
Meg-platelet isolation 
At day 8, the medium containing the released Meg-platelets was collected, 
centrifuged at 130g for 5’ at RT, to remove floating cells, and filtered through a 
PALL Purecell PL leukocyte filters for platelets (PALL Medical). 
The platelet suspension, with the addition of 0.35% HSA, was then centrifuged at 
1900g for 16’ at RT; supernatant was discarded and platelet pellet was 
resuspended with HEPES-Tyrode’s buffer (137 mmol/L NaCl, 2.8 mmol/L KCl, 1 
mmol/L MgCl2, 12 mmol/L NaHCO3, 0.4 mmol/L Na2HPO4, 0.35% HSA, 10 mmol/L 
HEPES, and 5.5 mmol/L glucose, pH 7.4) for aggregation and adhesion 
experiments, or human plasma for PFA-100 and Rotem experiments. 
 
Blood Collection and preparation of Platelet Rich Plasma (PRP) and Platelet 
Poor Plasma (PPP) 
Blood was collected by venipuncture of the antecubital vein of healthy volunteers 
who did not take antiplatelet drugs within 10 days before blood donation and who 
gave their informed consent to participate in the study. After the first 4 mL was 
discarded, whole blood (WB) was drawn with a 19-gauge needle without venous 
stasis into citrate-containing (1/10 volume of 0.129 mol/L sodium citrate) 
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evacuated tubes (Vacutainer, Becton Dickinson). Platelet Rich Plasma (PRP) was 
prepared by centrifugation of WB at 160g for 15’, at RT with brake off. For platelet 
poor plasma (PPP) blood was centrifuged at 1900g, 15’, at RT. 
 
Immunocytochemistry 
Meg-01 were seeded on gelatin-coated coverslip and were differentiated with VPA 
2mM. At day 8 Meg-01 were fixed in 1% paraformaldehyde at room temperature 
for 10 min, permeabilized in 0.1% Triton X-100 in phosphate-buffered saline for 5 
minutes. Immunodetection of Tissue Factor was carried out by incubating cells 
with mouse monoclonal anti-human Tissue Factor (4509, American Diagnostica) 
and by using the AlexaFluor 488 or 594-labelled goat anti-mouse IgG (Molecular 
Probes). Cells were also incubated with Alexa Fluor® 594 or 633 phalloidin 
(Molecular Probes) to selectively label actin-filaments and with Hoechst 33342 
(Molecular Probes) to stain the nuclei. The staining of cells were analyzed using a 
confocal microscopy LSM510 (Carl Zeiss, Germany). 
 
Flow cytometry  
Analysis of megakaryocyte ploidy. In order to analyze DNA content, Meg-01 cells 
were harvested at day 14 of culture with VPA 2mM and fixed with cold ethanol 
70% at -20°C overnight. Cells were then stained with CD41 PerCpCy5.5 (250ng) in 
the presence of propidium iodide 50 μg/mL and RNaseA 100 μg/mL in PBS-Triton 
0.1% solution, for 2h in the dark, at 4°C. After incubation, cells were analyzed by 
two-color flow cytometry (FACSCalibur flow cytometer; BD Biosciences). At least 
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50,000 events were collected. Data were analyzed offline using BD CellQuest™ Pro 
software.  
Meg-01 and Meg-platelet staining. All the samples were processed as follows: 
50.000 Meg-01 cells or CD34pos-MK were collected into a polypropylene tube. For 
Meg-platelets analysis, 100 µl of MK culture medium containing the released 
platelets was collected from the culture plates and transferred into a 
polypropylene tube. The antibodies were used at the following concentration: 
CD41 250ng,  CD61 500ng, CD107 60ng, TF-PE 250ng, Annexin V 10ng, TF4507 
250ng, TF4509 250ng, GpVI 1µg and α2β1 1µg. All the antibodies were incubated in 
presence of 10% FBS and EDTA 2mM for 15 minutes at RT, in the dark. The 
expression of CD61, CD41, GpVI and α2β1 was also evaluated upon stimulation with 
TRAP-6 25µM added to the sample with the antibodies. For intracellular staining 
cells were fixed with PFA 1% for 10 minutes and permeabilized with PBS-Triton 
0,1% for 15 minutes, at RT. 
MP staining and analysis. MP characterization was performed on Meg01 and 
CD34+ derived megakaryocytes supernatants. 100 µl of each supernatant sample 
was collected from the culture plates, transferred into a polypropylene tube and 
labeled 15 minutes at RT, in the dark. The labeling mix contained VPD, 7-AAD, 
CD61, CD107 and TF. VPD and 7-AAD staining were used to identify events with an 
intact plasma membrane and apoptotic bodies, respectively. Polystyrene calibrated 
beads (0.5, 0.9 and 3 µm) were used to set the instrument for MP detection and 
analysis. 
By using this gating strategy, MPs were defined as 7-AAD negative, VPD and CD61 
positive events and then the expression of CD107 and Tissue Factor was evaluated. 
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Samples were diluted in PBS and immediately analyzed by flow cytometer. 
Fluorescence Minus One (FMO) controls were used throughout all the stainings to 
assess non-specific fluorescence events. 
MP and Meg-platelet quantification. MPs and Meg-platelets were counted by 
Trucount tubes. 50µl of cells prepared for the staining were dispensed into 
Trucount tubes using reverse pipetting technique and analyzed by BD FACSAria 
IIUTM. The Flow rate was set at 1. Beads have been identified with a gate and 
10,000 events have been acquired in this gate. A gate including MPs or Meg-
platelets has been drawn. Calculation of MP and Meg-platelets count was obtained 
from the following equation: Number of beads acquired into the gate (10,000): 
number of events acquired into the MP or Meg-platelets gate = number of beads 
into the BD Trucountd tube (given by the company) : absolute number of MPs or 
platelets like.  
Samples were processed on a BD FACSAria IIUTM cell sorter, supplied with a 100 
µm nozzle, and further analyzed with a BD FACS DiVa SoftwareTM, version 6.1.3. 
The instrument was equipped with four lasers (laser 488, laser 633, laser 561 and 
laser 405) and a standard optical filter setup with a windows extension of 2. 
Cytometer Performances were checked by daily running BD Cytometer Setup and 
Tracking Beads. Compensation was performed using BD Comp Beads and manually 
corrected. Samples were acquired with a flow rate of 1,0 and a minimum of 10,000 
events was recorded. All parameters were plotted on logarithmic scales; threshold 
was set on FSC. Doublets and aggregates were excluded from the analysis based on 
a dual parameter dot plot in which the pulse ratio (signal area/signal high; y-axis) 
versus signal area (x-axis) was displayed.  
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Enzyme-Linked Immunosorbent Assay 
TF antigen levels in Meg-01, CD34+-derived megakaryocyte and Meg-platelets was 
determined by ELISA (Total Tissue Factor, Hyphen) according to the 
manufacturer’s instructions. Briefly, cells were lysed with β-octyl for 15 minutes at 
37°C and protein concentrations determined using Bradford's method. 200µl of 
cell lysate were incubated in duplicate in wells coated with a mouse monoclonal 
antibody against human TF, overnight at 4°C. The absorbance at 450 nm was 
measured and compared to the values obtained from a standard curve generated 
using known amounts of human tissue factor. 
 
RNA extraction and Real-time PCR  
Total RNA was isolated from cells using a miRNeasy Mini kit. Total RNA (400 ng) 
was reverse transcribed by using 200 U SuperScript® Reverse Transcriptase  and 
0.5 μg oligo(dT) primer together with the manufacturer’s buffer, dNTP mix (10mM 
each dATP, dGTP, dCTP and dTTP), and 40U RNaseOUT ™ Recombinant RNasi 
Inhibitor. Incubation was carried out at 50°C for 60 minutes. In order to prove that 
PCR products were RT-dependent and not due to contamination with genomic 
DNA, RNA was reverse-transcribed in the presence or absence of retro-
transcriptase. Real-time quantitative PCR was carried out on iCycler Optical 
System (Bio-Rad Laboratories) as previously described72. cDNA (50 ng) was 
incubated in 25 µL iQ™ SYBR® Green supermix containing specific primers as 
listed in Table I. Amplification of GAPDH was used to correct for fluctuations in 
input RNA levels. A 5-step dilution series of cDNA was used to obtain a linear 
equation in order to calculate the amplification efficiency (E= 10-1/slope) of each 
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reaction and used for Gene Expression MacroTM analysis (Biorad). The specificity 
of amplified products was verify by analysis of the melting curves obtained by 
stepwise increase of the temperature from 55°C to 95°C. Samples were run in 
triplicate and amplifications were confirmed three times.  
 
Table I. Primers used in real time-PCR 
Gene   Sequence (5'→3') Exon 
Amplicon 
length 
Concentration 
(nM) 
TF 
Forw tgatgtggataaaggagaaaactactgt 5 
93 bp 500 
Rev tctaccgggctgtctgtactctt 5 
GPIIIa 
Forw ctagtggaaagtccatcctgtatgtg 13 
83 bp 700 
Rev cactgagagcaggaccaccag 14 
COX-1 
Forw tgcccagctcctggcccgccgctt 5 
302 bp 300 
Rev gtgcatcaacacaggcgcctcttc 7 
GAPDH 
Forw ccacccatggcaaattcc 5 
89 bp 300 
Rev tcgctcctggaagatggtg 5 
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Platelet adhesion 
Platelet-like particles released from Meg-01 were separated by filtration as 
described above. After filtration Meg-platelets were centrifuged at 1500g, for 8 
minutes, at RT; the supernatant was discarded and the Meg-platelet pellet was 
resuspended with Tyrode-EDTA-HAS buffer. Meg-platelets were seeded onto 
fibrinogen-coated coverslip and TRAP-6 25µM was added in order to induced 
platelet adhesion. Platelet adhesion was performed simultaneously on platelets 
from PRP as positive control. 
 
Thrombin generation assay 
Samples were lysed in β-octyl/Hepes Saline buffer at a concentration of 3x106 
cells/mL and tested for their capacity to induce thrombin generation using the 
Calibrated Automated Thrombogram (CAT) assay. Twenty µl of platelet-free 
normal pooled plasma (POOL NORM, STAGO) were incubated for 10 min with 20 
µL of a cell sample in round-bottomed 96-well micro titer plates (Immulon 2HB, 
STAGO). To assess TF dependent contribution to thrombin generation, the CAT 
assay was performed after pre-incubation of cell samples with a neutralizing anti-
TF antibody (100 µg/ml, AD4501, polyclonal goat anti-human TF). Thrombin 
generation was started by the addition of a CaCl2/fluorogenic substrate mixture 
(FluCa Kit, STAGO) and fluorescence was read for 90 minutes in a Fluoroskan 
Ascent® reader (Thermo Labsystems, Helsinki, Finland) equipped with a 390/460 
filter set. In order to correct for inner filter effects and substrate consumption, 
each thrombin generation measurement was calibrated against the fluorescence 
curve obtained in the same plasma to which a fixed amount of thrombin-α2-
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macroglobulin complex was added (Thrombin Calibrator; Thrombinoscope BV). 
Thrombin generation curves were analyzed by dedicated software 
(Thrombinoscope BV, Maastricht, The Netherlands). Peak height (nM Thrombin), 
time-to-peak (ttPeak, minutes) and lag time (minutes) were used as main 
parameters determining thrombin generation. 
 
Platelet-like particles function tests  
The aggregating capacity of Meg-platelet was measured by optical aggregometry 
(ChronoLog model 490; Havertown, PA) using Born turbidometric method. Meg-
platelets were obtained as described above and resuspended in standard Tyrode’s 
buffer containing 0.35% BSA, to a ﬁnal concentration of 250,000 platelets/µl. Cells 
were stimulated with collagen (10µg/ml) or TRAP-6 (50µM) in presence of 
fibrinogen (40 mg/ml) and MgCl2 (1mM). Aggregation curves were registered and 
analyzed by AggroLink software (ChronoLog Corporation). 
 
Platelet function under high shear conditions  
The Platelet Function analyzer device (PFA-100®, Siemens Healthcare Diagnostics 
Inc., Deerfield) was used to evaluate Meg-platelet adhesion and aggregation on 
shear stress. Blood was collected as described above, centrifuged at 160g, for 15 
min, at RT and PRP was separated in order to obtain platelet-depleted blood. 800µl 
of platelet-free blood were reconstituted with Meg-platelet or autologous platelets, 
diluted to 200,000plt/µl with PPP (prepared by centrifugation of PRP at 1900g, for 
10 min, at RT) and analyzed in a collagen / epinephrine (CEPI) cartridge. 
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Thromboelastometry (ROTEM) 
Thrombelastography was performed with the Rotem coagulation analyzer (Tem 
International GmbH, Munich, Germany) using the NATEM assay. Briefly, 300µl of 
platelet-free blood or platelet poor plasma, prepared as described above, were 
reconstituted with Meg-platelets (control or TF–silenced platelets) or autologous 
platelets. All measurements were performed at 37°C after recalcification of the 
samples with 20 µL of 0.2 mol/L CaCl2, according to the manufacturer’s 
instructions. 
The following variables were recorded: clotting time (CT, time from addition of 
reagent to formation of clot with amplitude of 2 mm), clot formation time (CFT, 
time taken from CT until formation of clot with amplitude of 20 mm) and alpha 
angle (the angle of the tangent of the curve at the point that the CFT is reached) 
which indicate the dynamics of clot formation; CT parameter is influenced 
primarily by the activity of coagulation factors while CFT and alpha describe the 
kinetic of platelet and fibrin polymerization. The maximum clot firmness (MCF, the 
peak amplitude of the clot formed) gives information about clot strength and 
stability and is largely dependent on fibrinogen and platelets. The amplitude (A, 
amplitude of the clot at a specific time point) is a useful rapid indicator for the 
developing clot strengths, primarily influenced by platelets, fibrinogen and factor 
XIII. 
 
shRNA Knockdown of Tissue Factor in Meg-01 Cells 
For infection, three different target vectors were utilized: clone ID V2LHS_151505 
target sequence CTGTTATTACCATTAGCAT; clone ID V3LHS_371301 target 
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sequence AAGTCTACACTGTTCAAAT and clone ID V3LHC_410106 target sequence: 
TGGAGAGCTACTG CAAATGCT. Scrambled and GAPDH-GIPZ lentiviral particles 
were used as control. Megakaryoblastic cell line MEG-01 were transferred into a 
25 cm2 flask and incubated for 48 hours with viral particles diluted into growth 
media (1:200). After 48 hours, transduced cells were selected with medium 
containing puromycin (10 μg/ml) using the disappearance of all GFP-MEG-01 cells, 
determined by FACS analysis, and elimination of all MEG-01 cells from an 
untransduced control culture as selection end points. 
 
Statistical Analysis 
Data are expressed as the means ± SD. Differences between group were analyzed 
by using one-way ANOVA followed by Tukey's post-hoc t test (GraphPad Prism 
software) or Student’s paired or unpaired t-test (SPSS statistical package). A P 
value <0.05 was considered statistically significant. 
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RESULTS 
Meg-01 cell line characterization 
Meg-01 cells is a human megakaryoblastic cell line isolated from the bone marrow 
of a patient with Philadelphia chromosome-positive chronic myeloid leukemia and 
characterized for the first time in 1985 at the Faculty of Medicine of the University 
of Nagoya, Japan75. Meg-01 proliferate as a single cell suspension, only the 2% of 
these cells adhere (fig. 9), with an average doubling time of 50± 5,5 hours.  
 
Figure 9. Phase contrast image of Meg-01 cell line photographed with a 10x lens 
(AxioSkop, Zeiss). In this image it is possible to appreciate how the majority of the cells 
grow in suspension and only a small percentage of them adhere to the culture dishes. 
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Meg-01 cells are mostly round shaped, with a modal diameter of 25 to 40 µm, and 
have large round or ovoid nuclei with fine chromatin and one or more prominent 
nucleoli (fig. 10a). The plasma membrane is characterized by the presence of 
several cytoplasmic protrusion (fig. 10b).  
 
 
Figure 10. a) May-Grünwald Giemsa staining of Meg-01 photographed in bright field with a 
40x lens showing the round shape of megakaryoblasts, the large nuclei and the numerous 
nucleoli. b) Scanning electron microscope image of a Meg-01 cell showing the high number 
of protrusion on the plasma membrane.  
Results 
 
 43 
Treatment of meg-01 with agents, such as phorbol esters, valproic acid (VPA) or 
thrombopoietin, induced cell differentiation that resulted in cell adhesion (the 
percentage of the adherent cells increased up to 70%) (fig. 11) and in the 
acquisition of megakaryocyte’s characteristic phenotype.  
 
Figure 11. Phase contrast image of Meg-01 differentiated megakaryocytes by VPA 2mM 
differentiated to megakaryocytes (10x lens, AxioSkop microscope, Zeiss). Please note the 
morphological changes of the adherent megakaryocytes as compared to floating 
megakaryoblasts and the appearance of several nuclei. 
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As well as human megakaryocytes, Meg-megakaryocytes (Meg-MK) are 
multinucleated cells (fig. 12) indeed they don’t replicated and don’t do mitosis but 
they undergo endomitosis and become polyploid through repeated cycles of DNA 
replication. 
 
Figure 12. a) Phase contrast micrograph of a Meg-01 differentiated MK; b)bone marrow 
smear stained with May-Grünwald-Giemsa. Axioskop microscope (Zeiss) equipped with a 
40x lens. Please note in both cells the presence of several nuclei.  
 
Changes in ploidy during differentiation of Meg-01 was evaluated by propidium 
iodide staining. An example of the polyploidy analysis carried out on mature Meg-
MK is reported in figure 13a: the ploidy distribution obtained by flow cytometry 
showed that  approximately half of the Meg-MK population was 16N, 20% of cells 
being ≤8N and 28.2% being 32N or higher. In contrast, all megakaryoblasts were 
distributed among 2N and 4N (fig. 13b). 
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Figure 13. a) Ploidy distribution of VPA-differentiated Meg-MK. b) Ploidy distribution of 
Meg-01. 
 
 
The expression of population markers was evaluated by flow cytometry and 
immunocytochemistry: all Meg-MK express GpIIb (CD41), GpIIIa (CD61) (fig. 6a 
and c), GpIb (CD42) (fig. 14b) and vWF (fig. 14d). Moreover, the expression of 
GpIIb and GpIIIa is higher in Meg-MK compared to Meg-01 (fig 15a and b). 
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Figure 14. a) Flow cytometry evaluation of GpIIb (CD41) and GpIIIa (CD61) in Meg-
megakaryocytes. b) Flow cytometry evaluation of GpIb (CD42b) in Meg-megakaryocytes.  
(c-d) Immunofluorescence staining and confocal microscopy analysis of GpIIIa and von 
Willebrand factor expression in Meg-megakaryocytes. Note the typical proplatelets 
extending from the cell body. Scale bar, 20µm. 
a b 
c 
d 
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Figure 15. The expression of GpIIb (a) and GpIIIa (b) was assessed by flow cytometry both 
in megakaryoblasts and in megakaryocytes. The overlay shows an higher expression of 
both population markers in megakaryocytes compared to megakaryoblasts. 
 
Similary to what happens in human megakaryocytes, also Meg-MK emit long (up to 
500µm in length) thin cytoplasmatic processes called proplatelets (fig. 16) with the 
typical final tip (fig. 17) from which they release platelets. These extensions are 
characterized by multiple platelet-size swellings linked togheter by thin 
cytoplasmic bridges (fig. 16). 
 
Figure 16. a) Differential Interference Contrast (DIC) image of a Meg-MK (40x lens, 
AxioObserver microscope, Zeiss): arrows indicate platelet-size swellings along the 
proplatelet. 
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Figure 17. a) β-tubulin (green) immunostaining of a pro-platelet showing the 
characteristic final tip (20x lens, Apotome, Zeiss) b) Scanning electron micrograph of the 
final tip of a pro-platelet. 
 
 
Meg-Platelets release and characterization 
Meg-platelets production 
VPA-differentiated Meg-MK are albe to release platelet-like particles. We counted 
Meg-platelets by flow cytometry using Trucount beads. The platelet release 
occured in a costant manner during culture: one milion of Meg-MK release from 
7±3 milions platelet in one day, resulting in a total of 60-65 milions of platelets in 
seven days (fig. 18).  
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Figure 18. Daily release of platelets from VPA-differentiated Meg-MK. The number of 
megakaryocytes does not change during culture (grey line), while the number of platelets 
increased over time (black line). Counts were performed by flow cytometry with Trucount 
Beads. 
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Meg-Platelets: flow cytometric characterization 
Flow cytometry analysis showed that the physical properties (side and forward 
scatter) of Meg-Platelets are extremely similar to those of human platelets from a 
platelet rich plasma (fig. 19). 
 
Figure 19. Physical properties (side and forward scatter) of Meg-platelets and human 
platelets in a platelet rich plasma. 
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Almost all Meg-platelets express the typical platelet markers, GpIIb and GpIIIa, but 
only a fraction of them expressed α2β1 and GpVI (fig. 20a), as for human plaelets. 
The expression of all these platelet markers increased upon stimulation with 
thrombin receptor activator (TRAP-6) (fig. 20b), similarly to what occured in 
human platelets (fig. 20c). 
 
 
 
Figure 20. a) Flow cytometry evaluation of GpIIb, GpIIIa, α2β1 and GpVI expression 
(percentage of positive cells) in Meg-platelets. Modulation of the GpIIb, GpIIIa, α2β1 and 
Results 
 
 52 
GpVI expression (Mean Fluorescence Intensity) in Meg-platelets (b) and in human 
platelets (c) upon TRAP-6 (25 µM) stimulation. 
 
The capability of Meg-platelets to adhere to fibrinogen coated surface and to 
aggregate upon stimulation were also evaluated. After treatment with TRAP-6 
Meg-platelets were able to adhere to fibrinogen and spread (fig. 21). Aggregation 
was observed in response to both TRAP-6 and collagen (fig. 22).  
 
 
 
 
 
 
 
 
 
Figure 21. Differential Interference Contrast (DIC) micrograph of Meg-platelets adhering 
and spreading onto glass surfaces coated with fibrinogen upon stimulation with TRAP-6 
(25 µM).63x lens, AxioObserver, Zeiss. Scale bar, 50 µm. 
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Figure 22. a) Aggregation of washed Meg-platelets performed in the presence of MgCl2 (1 
mM), fibrinogen (40 mg/ml) and TRAP-6 25 µM (black line) or collagen 10 µg/ml (blue 
line). (b) Meg-platelet aggregates at the end of the aggregation assay. 
 
 
Finally, the haemostatic capacity of Meg-platelets was assessed by PFA-100 system 
(fig. 23) and by thromboelastometry (fig. 24). When used to reconstituted a 
platelet-depleted whole blood the haemostatic capacity of Meg-platelets was 
comparable to that obtained with whole blood reconstituted with autologous 
platelets. Thromboelastometry assays showed that platelet-depleted whole blood 
reconstituted with Meg-platelets and whole blood reconstituted with autologous 
platelets had similar clot formation time (CFT), α-angle and maximum clot 
firmness (MCF) (all parameters influenced by platelets) similar to those observed 
with whole blood. 
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Figure 23. The haemostatic capacity of platelet-depleted whole blood (WB) reconstituted 
with autologous platelets or Meg-platelets assessed by PFA-100 system. 
 
 
Figure 24. The haemostatic capacity of platelet-depleted whole blood (WB) reconstituted 
with autologous platelets or Meg-platelets assessed by thromboelastometry. 
MCF=maximum clot firmness; CFT=clot formation time; α-angle=angle between the 
tangent to the curve in the point 2 mm and the baseline. 
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Evaluation of Tissue Factor expression 
Evaluation of Tissue factor expression and functional activity in Meg-01 
In agreement with data published in 200352, TF mRNA expression was detected by 
quantitative real-time PCR in megakaryocytes. Notably, it was expressed, although 
at lower levels, also in megakaryoblasts and its expression gradually increased 
(threefold) during megakaryocyte differentiation (fig. 25a). This is a feature 
common to other transcripts, such as GpIIIa and cyclooxygenase-1, that showed an 
even much greater increase during differentiation (fig.25b).  
 
 
Figure 25. a)TF mRNA expression, evaluated by real time PCR, in megakaryoblasts and in 
Meg-MK at 5 and 10 days of differentiation with VPA. TF mRNA expression was 
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significantly (P<0.005) higher in megakaryocytes compared to megakaryoblasts. (b) 
Comparison of the relative amounts of TF, GpIIIa and COX-1 mRNAs in megakaryoblasts 
and megakaryocytes (setting to 1 the expression of each gene in megakaryoblasts). 
In line with the PCR results TF protein, measured by Elisa, was significantly more 
abundant in differentiated megakaryocytes (90±30 pg/mg protein) than in 
megakaryoblasts (50±10 pg/mg protein) (fig. 26).  
 
Figure 26. TF protein level assessed by Elisa. Meg-MK express roughly twice the amount of 
TF compared to megakaryoblasts. 
 
To better characterize TF distribution at the cellular level, surface and intracellular 
staining were assessed and analyzed by flow cytometry. TF was present on the 
surface of ~45% of megakaryoblasts and ~70% of megakaryocytes; when 
analyzed intracellularly, ~75% of megakaryoblasts and ~85% of megakaryocytes 
were TF-positive. Saturation of the antibody with recombinant TF protein before 
labelling completely abolished the staining, confirming the specificity of the 
antibody (Fig. 27).  
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Figure 27. Surface and intracellular (IC) expression of TF analyzed by flow cytometry. TF 
was present on the surface of 45.8±3% of megakaryoblasts and 72.3±8% of 
megakaryocytes and in the cytoplasm of 77.1±3% and 86.0±4% of megakaryoblasts and 
megakaryocytes, respectively. 
 
In order to assess whether TF expressed by megakaryoblasts and megakaryocytes 
was functionally active the thrombin generation assay was performed. 
Megakaryocytes showed a thrombin generation capacity higher than that of 
megakaryoblasts as suggested by the shorter lag time and time to peak (fig. 28). TF 
contribution to the thrombin generation capacity accounted for 40% and 78% for 
megakaryoblasts and megakaryocytes respectively, as indicated by the residual 
thrombin generated in the presence of a neutralizing TF antibody. 
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Figure 28. Thrombin generation assay performed with megakaryoblasts and 
megakaryocytes in the absence and presence of a neutralizing TF antibody (100 µg/ml). * 
P≤0.05; § P≤0.001.  
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Immunostaining and confocal microscopy analysis confirmed that TF was 
expressed on the cell surface in 70% of Meg-MK (fig. 29a), whereas almost 100% 
of the cells showed TF positive intracellular staining (fig. 29b). Moreover 
microscopy analysis showed that TF was present both in the cell body as well as in 
the pro-platelet tips (fig. 30). 
    
 
Figure 29. Immunofluorescence staining and confocal microscopy analysis of a) surface 
localization and b) intracellular localization of TF (green) in Meg-MK. Please note that in a) 
only the 70% of cells are TF positive and in b) all the cells express TF. Scale bar 50µm.  
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Figure 30. Intracellular immunofluorescence staining and confocal microscopy analysis of 
TF (green), actin filaments (red) and nuclei (blue) of a Meg-MK at day 14 of differentiation. 
Scale bar 20µm. 
 
Evaluation of Tissue factor expression and functional activity in Meg-
platelets 
In order to verify whether the presence of TF in the final tip could support the 
concept of a transfer of TF from megakaryocyte to nascent platelets, TF expression 
in Meg-platelets was evaluated. 
 
Flow cytometry analysis showed that TF was detectable in the cytoplasm of ~40% 
of Meg-platelets (fig. 31). These data reflect quite well the in vivo situation in 
humans where the percentage of TF-positive platelets in intracellular staining 
amounts to ~30-35% (fig. 31). 
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Figure 31. Surface and intracellular expression of TF in Meg-platelets and in human 
platelets evaluated by flow cytometry. TF was present on the surface of 20.1±5% of Meg-
platelets and 2.5±0.6% of human platelets; when analyzed intracellularly, 40±7% of Meg-
platelets and 35±7% of human platelets were positive for the antigen. 
 
The thrombin generation capacity of Meg-platelet showed that TF was functionally 
active and its contribution was significantly blunted by a neutralizing TF antibody 
(fig. 32a). Experiments performed with FVII- or FX-depleted plasma showed no 
thrombin generation, further supporting the key role of the Meg-platelet 
associated TF (fig. 32b). 
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Figure 32. a) Thrombin generation assay performed with Meg-platelets in the absence and 
in the presence of a neutralizing TF antibody (100 µg/ml). b) Thrombin generation assay 
performed with Meg-platelets in factor X deficient plasma. 
 
In agreement with previous data52, real-time PCR experiments showed that Meg-
platelets have TF mRNA (fig. 33a). This observation suggests that the possibility 
exists that both TF protein and mRNA are transferred from megakaryocytes to 
new platelets. Notably, the profile of the total RNA extracted from Meg-platelets is 
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virtually identical to that of human platelets (fig. 33b) and also the relative 
abundance of transcripts such as GpIIIa and Cox-1, besides TF, is similar in the two 
cell systems (fig. 33a). 
                         
 
Figure 33. a) Comparison of the relative amounts of TF, GpIIIa and COX-1 mRNAs in Meg-
platelets and in human platelets (setting to 1 the expression of GpIIIa in meg- and human-
platelets). (b) Virtual gels of total RNA extracted from Meg- and human-platelets as 
provided by Bio-Analyzer. c) Meg-platelets RNA showed an electropherogram similar to 
that of human platelets with the 18S peak higher than that of the 28S subunit.  
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Evaluation of Tissue factor expression and functional activity in CD34+-
derived megakaryocytes. 
In order to confirm that the TF expression in MEG-01 was not a feature of the 
transformed cell line, but reflected a mechanism occurring in physiological 
conditions, TF expression in human CD34+-derived megakaryocytes (CD34+-MK) 
and in their platelets (CD34+-plat) was evaluated. TF protein levels in CD34+-MK, 
measured by Elisa, was similar to what observed in Meg-MK (124±27 pg/mg 
protein  and 90±30 pg/mg protein, respectively). The thrombin generation 
capacity of CD34+-MK (fig. 34) was also comparable to that found in Meg-MK. 
 
Figure 34. Thrombin generation assay performed with CD34+-MK in the absence and in 
the presence of a neutralizing TF antibody (100 µg/ml). 
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Flow cytometry analysis of surface and intracellular TF expression was also 
comparable to that observed with Meg-01 both in CD34+-MK and in CD34+-
platelets. TF was present on the plasma membrane of 81±4.2% of CD34+-MK and 
29±2.6% of CD34+-platelets, while the intracellular expression accounted for a 
95.6±6.2% and 47±1.7% of positive cells for CD34+-MK and CD34+–derived 
platelets, respectively (Fig. 35).  
 
 
 
Figure 35. Surface and intracellular expression of TF in CD34+-MK analyzed by flow 
cytometry.  
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Immunostaining and confocal microscopy analysis performed in CD34+-MK 
adherent to fibrinogen coated slides showed that TF was present both in the cell 
body as well as in proplatelet tips, as observed in Meg-MK (fig. 36). 
 
Figure 36. Intracellular immunofluorescence staining and confocal microscopy analysis of 
TF (green), actin filaments (red) and nuclei (blue) of a megakaryocyte at day 14 of 
differentiation. Scale bar 10µm. 
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Effect of Tissue factor silencing on Meg-01 
In order to dissect the contribution of platelet-TF to the global platelet haemostatic 
capacity, TF was silenced in Meg-01 and its expression and function in Meg-
megakaryoblast and in the megakaryocyte-shed platelets were assessed. Infection 
of Meg-01 with GIPZ lentiviral shRNA particles (three different target vectors) 
against human TF significantly prolonged the doubling time of the cells (62±6 and 
145± 9 hours) underlying the pivotal role of TF not only in coagulation but also in 
cell proliferation. With this experimental strategy a significant reduction of TF 
antigen in megakaryoblasts was observed. Flow cytometryc analysis showed an 
almost negligible expression of TF in the silenced Meg-01(fig. 37a), and this finding 
is confirmed by ELISA assays (fig. 37b).  
  
Figure 37. a) Flow cytometry evaluation of intracellular TF expression in wt Meg-01, in 
Meg-01 infected with GIPZ lentiviral shRNA particles to silence TF (shTF301, shTF106 and 
shTF505 target vectors) and in shRNA Scrambled Negative Control treated Meg-01. (b) TF 
protein levels, assessed by Elisa (*P=0.001), in megakaryoblasts and Meg-01 infected with 
GIPZ lentiviral shRNA particles to silence TF (shTF301, shTF106 and shTF505 target 
vectors) and shRNA Scrambled Negative Control treated cells.  
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Immunostaining and confocal microscopy analysis performed in Meg-MK showed 
no TF expression in TF-silenced Meg-MK compared to control megakaryocytes (fig. 
38).  
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Figure 38. Intracellular immunofluorescence staining and confocal microscopy analysis of 
TF (red), actin filaments (yellow) and nuclei (blue) of a control Meg-MK (left panel) and a 
TF-silenced Meg-MK (right panel). Please note that TF-silenced Meg-MK are GFP positive. 
Scale bar 20µm.  
 
 
The decreased TF expression observed in silenced megakaryoblasts was reflected 
in a consistent reduction of TF expression in the released platelets as assessed by 
flow cytometry. Only the 5% of TF silenced Meg-platelets were TF positive 
compared to 20% TF positive control Meg-platelets (fig. 39).  
 
 
Figure 39. Flow cytometric evaluation of intracellular TF expression of platelets derived 
from shRNA Scrambled Negative Control treated cells and from shTF301 silenced Meg-01. 
 
The reduction in TF expression was paralleled by a significant reduction in 
thrombin generation capacity of silenced megakaryoblasts, megakaryocytes and 
platelets. Silenced megakaryoblasts, Meg-Mk and Meg-platelets showed a delay in 
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the onset of the thrombin generation curve reflecting in a significant increase of lag 
time and time to peak (fig. 40) compared to control cells. 
 
 
Figure 40. TF activity assessed by Thrombin Generation Assay in megakaryoblasts, 
megakaryocytes and Meg-platelets (*P<0.0001). 
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The contribution of platelet-TF to the global platelet haemostatic capacity is 
further emphasized when the kinetic of clot formation was assessed in a platelet-
rich plasma (PRP). Platelet-depleted whole blood reconstituted with TF-silenced 
platelets or PRP showed a longer CFT and lower MCF and α-angle compared to 
platelet-depleted whole blood reconstituted with control Meg-platelets (fig. 41). 
 
Figure 41. Global platelet haemostatic capacity analyzed by thromboelastometry in 
platelet-depleted whole blood (left) and plasma (right), reconstituted with control Meg-
platelets or with TF-silenced Meg-platelets. Representative reaction curves (TEMograms) 
are shown. 
 
Tissue factor expression in microparticles 
TF-positive MPs have been found in vivo. Since both megakaryocytes and platelets 
release MPs, we characterized them for TF expression. First, MPs gate was 
assessed using polystyrene calibrated beads (0.5, 0.9 and 3 µm) to set the flow 
cytometer for MP detection and analysis (fig. 42a). Moreover, VPD and 7-AAD 
staining were used to identify events with an intact plasma membrane and 
apoptotic bodies, respectively. By using this gating strategy, MPs were defined as 
7-AAD negative, VPD and CD61 positive events (fig. 42b) and then the expression 
Results 
 
 73 
of CD107 and Tissue Factor was evaluated. Flow cytometry analysis showed that 
the majority (75 ± 7%) of MPs released in the medium were from megakaryocytes 
(CD61pos/CD107aneg events). The TFpos MPs accounted for 20%, 13% being from 
megakaryocytes and 5% from platelets (fig. 42c).  
Conversely, TF expression on MPs derived from silenced Meg-01 was almost 
negligible (fig. 42d). 
 
Figure 42. (a) The gating strategy for MP identification is shown: 1 µm calibrated beads 
were used to set the threshold size and to draw the MP gate. (b) The CD61 and VPD 
positive events within the MP gate were identified and analyzed for the expression of TF 
and CD107. CD107 positive MPs were from platelets, whereas CD107 negative MPs were 
from megakaryocytes. (c) Flow cytometric evaluation of surface TF expression of MPs 
derived from shRNA Scrambled Negative Control treated cells and (d) from shTF301 
silenced Meg-01. 
. 
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DISCUSSION 
In 2000 Giesen et al. postulated that thrombus formation and propagation, upon 
atherosclerotic plaque rupture, could take advantage of blood-born tissue factor: 
circulating platelets, carrying tissue factor (TF) derived from microparticles, may 
themselves trigger the activation of the coagulation cascade50. Since then, several 
papers have documented the presence of TF in human platelets, suggesting that at 
least three mechanisms are involved in the presence of TF in platelets: 1) the 
microparticle-transfer mechanism; 2) the storage within the α-granules and the 
open canalicular system and 3) the de novo protein synthesis from the TF specific 
messenger RNA (mRNA). A recent study showed that the transfer of mRNAs from 
megakaryocytes to platelets is not a random event, but occurs through a fine-tuned 
mechanism that select the mRNA content that will be provided to platelets. In 
particular, only the mRNAs that, when transcribed and transferred from the 
nucleus to the cytoplasm of the megakaryocyte, bind to specific RNA-binding 
proteins will be transferred into the nascent platelets through the complex system 
of microtubules. By contrast, mRNAs that did not bind to these proteins will be 
translated into protein that, upon storage into the granules, will be transferred to 
platelets44. In 2003 our group provided the evidence that human CD34+-derived 
megakaryocytes express the TF mRNA52. Thus, it can be speculated that the TF 
mRNA detectable in platelets could be the result of a direct transfer from 
megakaryocytes, but to date the evidence for this mechanism is still lacking. 
Moreover, the presence of TF protein in human megakaryocyte has never been 
reported. Conversely, it is commonly believed that the only mechanism 
responsible for the presence of TF in platelets is through the uptake of TF-positive 
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microparticles released by activated endothelial cells or leukocytes. In order to 
verify whether the transfer of TF from megakaryocytes to platelets is an existing 
process, we took advantage from a commercially available human 
megakaryoblastic cell line, called Meg-01, able to differentiate into platelet-
releasing megakaryocytes. We first validated this in vitro system, providing the 
evidence that Meg-platelets have the same physical (size and intracellular 
complexity) and antigenic characteristics of human platelets. Moreover, we 
reported that Meg-platelets are functionally active, in a manner comparable to 
human platelets, being able to aggregate in response to collagen and TRAP-6, to 
adhere to fibrinogen and spread onto fibrinogen-coated surface, and to contribute 
to the hemostatic capacity of the blood, when tested by thromboelastometry. 
By using this well characterized in vitro model able to recapitulate megakaryocyte 
differentiation and platelet biogenesis, we provide consistent evidence that TF is 
an endogenously synthesized protein that characterizes megakaryocyte 
maturation. Since the cell system used allowed us to study mRNA and protein 
expression in the absence of any crosstalk with other cell or MP, here we provide 
the evidence for the direct transfer of both TF mRNA and protein from 
megakaryocytes to a subset of platelets where it contributes to their thrombin 
generation capacity. Of interest, the percentage of TF positive platelets that we 
observed in vitro (both with Meg-platelets and with CD34+-derived platelets) is 
virtually identical to the amount found in blood from healthy individuals (30-
40%). This striking data suggests that a fine-tuned mechanism, which deserves 
further investigation in order to dissect the molecular pathways involved in its 
regulation, is responsible for the controlled delivery of TF from megakaryocytes to 
Discussion 
 
 77 
platelets. It is plausible that such a mechanism may account for the heterogeneity 
in platelet function according to the transcriptome and protein content present in 
different subset of platelets. Indeed, studies carried out in the last 15 years have 
highlighted that platelets are involved not only in hemostasis and in thrombotic 
events responsible for the clinical manifestation of cardiovascular diseases such as 
myocardial infarction, stroke and peripheral ischemia, but they are actively 
involved in inflammatory processes, angiogenesis and tumor metastasis82,83, and in 
several pathological conditions such as Alzheimer’s disease84, systemic sclerosis85, 
rheumatoid arthritis86 and systemic lupus erythematosus87. Recently, Stalker and 
colleagues proposed a new model of thrombus formation, suggesting that the 
thrombus is not an homogeneous mass but it is constituted by a core of fully 
activated platelets overlaid by a shell of less-activated, mostly unstable platelets 
(fig. 43). These data further support the concept of platelet heterogenicity, 
showing that the haemostatic thrombus is not a homogeneous mass in which all 
platelets are activated to the same extent81. 
 
Discussion 
 
 78 
 
Figure 43. Structural heterogeneity in the haemostatic plug. There are distinct regions 
within the haemostatic thrombus where platelets are either more or less activated and 
where fibrin tends to accumulate. A stable core of closely packed, fully activated platelets 
is overlaid by an outer shell of less-activated platelets, with a boundary zone in between. 
 
 
A major issue related to the finding of platelet-associated TF is the demonstration 
of its relative contribution to the in vivo thrombus formation. By taking advantage 
from a TF silencing approach, we developed three megakaryoblast cell lines stably 
under-expressing TF. This resulted in a prolonged doubling time, emphasizing the 
pivotal role of TF not only in the activation of the coagulation cascade but also in 
cell proliferation21. The capacity to differentiate and to release platelets were not 
affected. As a consequence of this manipulation the percentage of TF-positive 
platelets released by these cell lines significantly decreased and this was paralleled 
by a significant reduction in thrombin generation capacity. The contribution of 
platelet-TF to global platelet haemostatic capacity was further emphasized when 
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the kinetic of clot formation was assessed by thromboelastometry in a platelet-rich 
plasma.  
Our data show that TF silencing in Meg-megakaryoblasts resulted in a significant 
reduction of TF protein expression. As a consequence we also observed a decrease 
in thrombin generation of whole blood reconstituted with TF-silenced platelets 
providing the evidence of the contribution of the platelet-associated TF expression 
to the thrombus formation.  
TF is not the only coagulation factor present in platelets. Indeed, platelets contain 
several coagulation factors (FV, FIX, FXI, FXIII, fibrinogen, von Willebrand factor, 
TFPI, etc) which are promptly released on the cell surface upon platelet activation. 
Of note, for some of the above mentioned coagulation factors (FXI, FXIII, TF, TFPI, 
von Willebrand factor) the presence of the corresponding mRNA has also been 
reported and this finding is of particular relevance if the biosynthetic capacity of 
platelets is considered. 
 
 
In conclusion all these data show that TF is expressed both by megakaryoblasts 
and megakaryocytes, and its expression increases during megakaryocyte 
differentiation. Furthermore, this in vitro approach, devoid of any cross-talk with 
other cells or microparticles, allows us to show that human megakaryocytes are 
able to transfer TF to a subset of platelets. Therefore platelets may express TF 
independently of the interaction with other cells, thus providing these cells with 
the capacity to control also the generation of thrombin. This is of particular 
relevance in view of the observation that under pathological conditions the 
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number of TF positive cells significantly increases and this may be due to 
alteration in megakaryocyte behavior72,56-58. This mechanism may represent a 
potential target for therapeutic intervention against the formation of platelet 
thrombi. The Meg-megakaryocytes and Meg-platelets in vitro model has provided 
novel insights into the contribution of platelets and platelet-derived TF in the 
activation of the blood coagulation. This model will also be useful for the 
assessment of molecular mechanisms responsible for the presence of an increased 
number of TF positive platelets in several diseases (cardiovascular diseases, cancer 
and autoimmunity diseases, etc). Finally, this model can be used to study 
megakaryocytes and platelets in diseases characterized by metabolic 
abnormalities associated with cardiovascular diseases, such as diabetes. Moreover, 
the pharmacological modulation of megakaryocyte-derived as well as platelet-
derived TF can also be investigated. 
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ABSTRACT 
Tissue factor is the main activator of the blood coagulation cascade and for this 
reason levels of TF are not easily detectable in cells in contact with blood under 
physiological conditions. By contrast, in pathological conditions endothelial cells 
and monocytes can be induced to express TF68. Induced-TF is present in 
atherosclerotic plaques (vessel wall-derived TF) and several studies in the past 
have documented its role in the plaque thrombogenicity33,35. At the end of the last 
century it was reported that, under physiological conditions, TF positive 
microparticles (MPs) circulate in the blood (blood-borne TF) and their number 
further increases in pathological conditions47,51. These microparticles, which arise 
mainly from activated endothelial cells and monocytes, could fuse with other cells 
conferring them the ability to activate coagulation69. 
Giesen et al. in 2000 showed the presence of TF in human platelets through this 
mechanism50. Since then several papers have documented the presence of TF in 
human platelets by using different approaches52-55,70-73. Despite this in-depth 
characterization, the platelet-associated TF is matter of controversy by some 
authors that, failing to identify TF in platelets, argue that the published data are 
artifacts, thus generating an ongoing debate73,74.  
To date two main “cellular entities” may be responsible for the presence of TF in 
platelets: TF-positive MPs derived from different activated cell types, as proposed 
by Nemerson’s group, and megakaryocytes that transferring TF mRNA to platelets 
make them autonomous in the synthesis of the protein. In this regard, ten years 
ago our group provided the evidence that human megakaryocytes contain TF 
mRNA53. The platelet transcriptome derives from megakaryocytes through finely 
Abstract 
 
 83 
tuned mechanisms43,44. The direct evidence that megakaryocytes transfer TF 
mRNA to platelets, however, is still missing; similarly, it has never been 
investigated whether megakaryocytes express TF protein that can be transferred 
to platelets; finally, the contribution of platelet TF to clot formation has never been 
assessed. To test these hypothesis we took advantage of a well-characterized 
human megakaryoblastic cell line, Meg-01, able to differentiate into 
megakaryocytes and to release platelets in vitro75. This approach allowed us to 
analyze TF mRNA and protein expression during the differentiation from 
megakaryoblasts to megakaryocytes and in the released platelets in the complete 
absence of any other “contaminating” cell that might be a source of microparticles. 
The expression of TF protein by Meg-01 and Meg-derived platelet (Meg-platelets) 
was confirmed in human megakaryocytes differentiated from CD34+ cells. Finally, 
TF mRNA was silenced in Meg-01 megakaryoblasts showing that megakaryocytes, 
Meg-platelets and MPs were almost devoid of TF. 
Using a combination of cell biology, flow cytometry, confocal microscopy and 
biochemical analyses here we show evidence for the first time that functionally 
active TF is expressed in human megakaryocytes, and that they transfer this 
protein to platelets and to microparticles (MPs). TF downregulation in 
megakaryoblasts by lentiviral shRNA particles almost completely abolished its 
expression in megakaryocytes, platelets and MPs. Furthermore, TF silencing leads 
to a decrease of the thrombin generation by megakaryocytes which is reflected on 
a decrease in thrombin generation by platelets, suggesting that the platelet-
associated TF may contribute to the haemostatic capacity of whole blood. 
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Taken together all these data shoe the evidence that human platelets and MPs 
carry a megakaryocyte-derived TF which is functionally active and able to trigger 
thrombin generation.  
Finally, this in vitro model may be used to investigate the modification in platelet 
transcriptome and functionality observed in several diseases, such as 
cardiovascular disease, diabetes and cancer. 
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